# OnCo record tenosynovial-giant-cell-tumour (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tenosynovial-giant-cell-tumour/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tenosynovial-giant-cell-tumour" ;
  schema:name "Tenosynovial giant cell tumour (TGCT)"@en ;
  schema:alternateName "TGCT"@en, "Pigmented villonodular synovitis"@en, "PVNS"@en, "Giant cell tumour of the tendon sheath"@en ;
  schema:description "TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."@en ;
  schema:url <https://onco.cc/cancers/tenosynovial-giant-cell-tumour/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Giant-cell_tumor_of_the_tendon_sheath> ;
  schema:citation <https://www.cancer.gov/types/soft-tissue-sarcoma>, <https://doi.org/10.1016/S0140-6736(24)00885-7>, <https://doi.org/10.1016/S0140-6736(19)30764-0>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor> ;
  onco:tag "nci-coverage", "rare", "sarcoma" ;
  onco:related <https://onco.cc/cancers/desmoid-tumour/>, <https://onco.cc/cancers/dermatofibrosarcoma-protuberans/>, <https://onco.cc/cancers/pecoma/>, <https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/limb-salvage-surgery/> ;
  onco:targets <https://onco.cc/targets/csf1r/> ;
  onco:drugs <https://onco.cc/drugs/pexidartinib/>, <https://onco.cc/drugs/vimseltinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/nilotinib/> ;
  onco:companies <https://onco.cc/companies/deciphera/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:pathways <https://onco.cc/pathways/tumor-microenvironment/> ;
  onco:terms <https://onco.cc/terms/rare-cancers/> ;
  onco:trials <https://onco.cc/trials/motion/>, <https://onco.cc/trials/nct05417789/>, <https://onco.cc/trials/nct05804045/>, <https://onco.cc/trials/nct04488822/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tap-lancet/>, <https://onco.cc/key-papers/paper-gelderblom-lancet/> ;
  onco:pipeline <https://onco.cc/drugs/vimseltinib/>, <https://onco.cc/trials/motion/>, <https://onco.cc/drugs/emactuzumab/>, <https://onco.cc/drugs/pimicotinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/drugs/vimseltinib/>, <https://onco.cc/drugs/pexidartinib/>, <https://onco.cc/trials/motion/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/nilotinib/> .